June 19, 2025

Single Psilocybin Dose Yields Long-Term Cancer Relief

A single psilocybin dose combined with therapy led to lasting reductions in depression and anxiety for cancer patients two years after treatment, according to new research.

Conexiant

June 18, 2025

Dream Recall Tied to Sleep Style

A new study of over 200 adults links dream recall to specific sleep patterns and mental traits such as mind wandering, highlighting how age, interference, and seasonal changes affect whether dreams are remembered.

Conexiant

June 16, 2025

Short, Insufficient Sleep Tied to Anxiety

A study found that both short sleep duration and insufficient sleep perception were linked to higher risks of anxiety and fatigue but not depression.

Conexiant

June 16, 2025

Cytisinicline Shows Efficacy In Smoking Cessation Trial 

A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.

Conexiant

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 12, 2025

Medical Oddities: 6 Foot Moves Possibly Worth Prescribing

Strong feet, smarter carbs, test kits, and tea—this roundup’s got range.

Conexiant

June 09, 2025

Sleep Signals May Shape Survival Odds

A new study found that a shorter time gap between melatonin production and sleep midpoints may be linked to longer survival among women with advanced breast cancer.

Conexiant

June 09, 2025

Gray and Blazed: Pot’s Risky New Demographic

As cannabis use rises among older adults, new studies reveal surprising health risks—from ER visits to potential dementia links.

KFF Health News

June 06, 2025

Can At-Home Melatonin Testing Work?

At-home dim light melatonin onset assessments were 92% successful in youth with ADHD symptoms, regardless of symptom severity.

Conexiant